Bain Capital Life Sciences Investors, LLC Nuvalent, Inc. Transaction History
Bain Capital Life Sciences Investors, LLC
- $298 Million
- Q1 2025
A detailed history of Bain Capital Life Sciences Investors, LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Bain Capital Life Sciences Investors, LLC holds 1,447,267 shares of NUVL stock, worth $111 Million. This represents 34.45% of its overall portfolio holdings.
Number of Shares
1,447,267
Previous 1,447,267
-0.0%
Holding current value
$111 Million
Previous $113 Million
9.4%
% of portfolio
34.45%
Previous 30.59%
Shares
4 transactions
Others Institutions Holding NUVL
# of Institutions
226Shares Held
61MCall Options Held
334KPut Options Held
199K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.38 Billion32.3% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$404 Million19.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.52MShares$347 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$232 Million0.01% of portfolio
-
Commodore Capital LP New York, NY1.86MShares$142 Million12.88% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.29B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...